Taiga Biotechnologies, Inc.'s technology is centered around boosting the immune system to better fight disease.

BRAND NEW CLASS OF CELL THERAPY

TBX-4000 = TAT PROTEIN + MYC PROTEIN
  • TBX-4000 is a proprietary protein of Taiga Biotechnologies, Inc. and is a fusion of the Trans-Activator Transcription (TAT) protein and the MYC protein. TBX-4000 is crucial to the development and function of TBX-3400 and TBX-2400.​

TURNING UP THE IMMUNE SYSTEM
  • MYC is the key regulator of cellular function.

  • TAT is the “payload” carrier that enables TBX-4000 to penetrate the cell membrane.

  • Once inside the cell, MYC is shuttled to the nucleus where it exerts its function.

check_edited.png

Reviewed By US FDA, EMA, Japan MHLW, Israel MoH

check_edited.png

TBX-4000 master file with the FDA supports two active INDs

Our-Key-Diference_PPT_Taiga_vFOL[14].png

MULTIPLE APPLICATIONS

Technology-Platform_PPT_Taiga_vFOL[44].png

HOW IT WORKS COMPARED TO OTHER THERAPIES

T-Cell Activation

Activation of the T-cell

T-cells identify tumor cells and become activated through a series of interactions.

When activated, the T-cell:

  • Targets and kills the tumor cell.

  • Proliferates, creating more T-cells that are able to identify and kill the tumor cell.

Tumor Evading Attack

Evade attack from the T-cell

Tumors evade T-cell attack by disguising themselves as “self” cells through the use of immune checkpoint receptors on its cell surface.

Two Mechanisms:

  • Certain Immune Checkpoints compete for the Signal 2 binding site on the Tumor Cell, inhibiting Signal 2 from occurring.

  • Other Immune Checkpoints interactions occur which lead to further inactivation of the T-Cell.

Checkpoint Inhibitors

Blocking the Immune Checkpoint Receptor

Competitors have developed therapies that use one or a combination of checkpoint inhibitors to block the interaction.

Issues:

  • Can become Relapsed or Refractory to the treatment.

  • Severe Toxicities, Autoimmune complications.

TBX-3400

Down-regulate the Checkpoint Receptors

We have data that shows TBX-3400 cells show decreased expression of immune checkpoint receptors.

Without these checkpoint receptors expressed, the T-cell is able to become activated, recognize the tumor and kill it.

 

Advantages:

  • Simple approach, down-regulates checkpoints.

  • Agnostic to solid tumor type.

  • Autologous, well-tolerated.

T-Cell Activation.png
Tumor Evading Attack.png
Checkpoint Inhibitors.png
TBX-3400.png